ECO Animal Health Group (LSE:EAH) posted a solid set of half-year results for 2025, with revenue rising 19% to £39.4 million and gross margins improving to 49.6%. Growth was driven by stronger sales volumes, price optimisation, and reduced input costs, supporting an adjusted EBITDA of £3.0 million. The company also achieved a major R&D milestone, securing a Positive Opinion from the European Medicines Agency for its poultry vaccine, ECOVAXXIN® MS. This development clears a path for commercial launch in the EU in the second half of 2026 and marks meaningful progress in ECO’s innovation pipeline.
ECO Animal Health’s outlook benefits from its sound financial footing and constructive technical signals. Nevertheless, an elevated P/E ratio raises questions around valuation, and uneven revenue trends introduce some risk to forward profitability. Limited disclosure from earnings calls or corporate updates provides few additional data points.
More about Eco Animal Health
ECO Animal Health is a global veterinary pharmaceutical company specialising in treatments and vaccines for pigs and poultry. Headquartered in the UK, the business markets its products worldwide and holds regulatory approvals in more than 70 countries.
Leave a Reply